## Pks13-TE inhibitor 3

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-151599 3031462-62-8 C <sub>21</sub> H <sub>18</sub> FNO <sub>5</sub> 383.37 Bacterial Anti-infection Please store the product under the recommended conditions in the Certificate of Analysis	
	Analysis.	

BIOLOGICAL ACTIVITY				
Description	Pks13-TE inhibitor 3 (compound 23) is a 13-Thioesterase (Pks13-TE) inhibitor (IC <sub>50</sub> =1.55 μM). Pks13-TE inhibitor 3 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0625-0.25 μg/mL). Pks13-TE inhibitor 3 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB <sup>[1]</sup> .			
IC <sub>50</sub> & Target	IC50: 1.55 μM (Pks13-TE) <sup>[1]</sup> .			
In Vitro	Pks13-TE inhibitor 3 (0-5.43 μM; 7 days) demonstrates potent activities against DS (drug-susceptible Mtb strain)-         tuberculosis)-TB and DR (drug-resistant strain of Mtb-tuberculosis)-TB strains with MIC range of 0.0625-0.25 μg/mL <sup>[1]</sup> .         MCE has not independently confirmed the accuracy of these methods. They are for reference only.         Cell Viability Assay <sup>[1]</sup> Cell Line:       DS (drug-susceptible Mtb strain)-tuberculosis (V4207), MDR (multidrug-resistant strain of Mtb-strain)			
	Cett Line:	Mtb, resistance to isoniazid and rifampin)-tuberculosis (V4207), MDR (Multidug-resistant strain of (extensively drug-resistant strain of Mtb resistant to isoniazid, rifampin, levofloxacin ofloxacin, and kanamycin)-tuberculosis (TF274 and R506) strains		
	Concentration:	0-5.43 μM (0-2048 μg/mL)		
	Incubation Time:	7 days		
	Result:	Inhibited V4207/DS Mtb strain (MIC=0.125 $\mu g/mL$ ), V2475/MDR (MIC=0.125-0.25 $\mu g/mL$ ), KZN494/MDR (MIC=0.0625-0.125 $\mu g/mL$ ), TF274/XDR (MIC=0.0625 $\mu g/mL$ ) and R506/XDR (MIC=0.0625 $\mu g/mL$ ) Mtb strains.		

## REFERENCES

[1]. Zhang W, et al. Structure-Based Optimization of Cournestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for Mycobacterium tuberculosis Treatment. J Med Chem. 2022 Oct 13;65(19):13240-13252.

Product Data Sheet

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA